Johnson & Johnson (JNJ): Raises 2026 EPS outlook as Q3 sales rise 5.9%
Image: AI-generated image (ElevenLabs)
J&J raised its 2026 adjusted EPS outlook to $11.05-$11.15 as Q3 sales rose 5.9% to $25.4B, led by Innovative Medicine (+7.7%). Adjusted EPS of $2.59 fell 7.5%; reported EPS was $0.09 on a talc settlement charge. Stelara erosion is still a drag.
Why it matters J&J is a bellwether for large-cap pharma and medtech. Cancer and immunology drugs are outgrowing the Stelara decline, but one-off litigation costs show how much legal risk still sits on the balance sheet.
What we verified J&J's 8-K confirms Q3 sales of $25,399M (+5.9%), adjusted EPS of $2.59 versus $2.80, reported EPS of $0.09 versus $2.12, Innovative Medicine sales of $16,757M and MedTech of $8,642M (+2.5%), and 2026 adjusted EPS guidance of $11.05-$11.15. CNBC and Seeking Alpha report the same beat and raised outlook.
For information only. Not financial advice. See our disclaimer and editorial standards . Spotted an error? Tell us .
